Novratis and BeiGene’s PD-1 drug falls victim to FDA approval delay

July 20, 2022

Illumina Decides to Spin Off Grail

June 6, 2024

Gilead gives Arcellx $285 million to extend agreement for BCMA cell treatment

November 17, 2023

Must Read

Top 10 Trends Reshaping Biotech R&D Infrastructure

June 29, 2026

The Rise of Multi-Omics in Drug Development

June 29, 2026

Ollin Brings in $330M to Advance Eye Disease Drug Through Phase 3 Trial

June 29, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

Ollin Brings in $330M to Advance Eye Disease Drug Through Phase 3 Trial

Epicrispr Reports Increased Muscle Volume in Early-Stage FSHD Trial of EPI-321

cAMPfield Plans Mid-Stage Ulcerative Colitis and Crohn’s Disease Trials for Prifemilast

Definium’s LSD Formula Delivers Stunning Late-Stage Results

BIO 2026: A Saudi sovereign wealth fund business and Flagship sign a research partnership

Biogen Pens $1B Deal to Acquire RayThera, Bagging Preclinical Immunology Assets

Eli Lilly Secures Global Rights to AlzeCure Alzheimer’s Drug Candidate in Deal Worth Over $1 Billion

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Top 10 Trends Reshaping Biotech R&D Infrastructure

The Rise of Multi-Omics in Drug Development

The Coming Talent Crisis in Life Sciences

How AI Is Changing the Economics of Drug Discovery

Commercial

Lyell to pay $40M For Colorectal Cancer CAR-T Therapy

Editor Picks

Novratis and BeiGene’s PD-1 drug falls victim to FDA approval delay

Illumina Decides to Spin Off Grail

Gilead gives Arcellx $285 million to extend agreement for BCMA cell treatment

Must Read

Top 10 Trends Reshaping Biotech R&D Infrastructure

The Rise of Multi-Omics in Drug Development

Ollin Brings in $330M to Advance Eye Disease Drug Through Phase 3 Trial

Hot Topics

About Us

Follow Us